×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ARVN – arvinas, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ARVN
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/21
10:30 am
arvn
Did Arvinas, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - ARVN
Medium
Report
Did Arvinas, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - ARVN
11/21
10:00 am
arvn
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Arvinas, Inc. (ARVN) And Encourages Investors to Reach Out
Medium
Report
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Arvinas, Inc. (ARVN) And Encourages Investors to Reach Out
11/21
05:12 am
arvn
HPK1 Inhibitors Pipeline Market Research Report 2024: Therapeutics Assessment of 10+ Drugs by Product Type, Stage, Route of Administration, and Molecule Type [Yahoo! Finance]
Medium
Report
HPK1 Inhibitors Pipeline Market Research Report 2024: Therapeutics Assessment of 10+ Drugs by Product Type, Stage, Route of Administration, and Molecule Type [Yahoo! Finance]
11/20
12:15 pm
arvn
Arvinas, Inc. (ARVN) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights
Low
Report
Arvinas, Inc. (ARVN) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights
11/20
12:00 pm
arvn
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN
Low
Report
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN
11/20
10:00 am
arvn
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Arvinas, Inc. (ARVN) And Encourages Stockholders to Reach Out
Medium
Report
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Arvinas, Inc. (ARVN) And Encourages Stockholders to Reach Out
11/20
09:31 am
arvn
Arvinas, Inc. (NASDAQ: ARVN) had its price target lowered by analysts at BMO Capital Markets from $90.00 to $88.00. They now have an "outperform" rating on the stock.
Medium
Report
Arvinas, Inc. (NASDAQ: ARVN) had its price target lowered by analysts at BMO Capital Markets from $90.00 to $88.00. They now have an "outperform" rating on the stock.
11/19
03:45 pm
arvn
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN
Low
Report
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/19
06:00 am
arvn
Form 8-K ARVINAS, INC. For: Nov 18
Medium
Report
Form 8-K ARVINAS, INC. For: Nov 18
11/14
01:24 pm
arvn
Form SC 13G/A ARVINAS, INC. Filed by: PRICE T ROWE ASSOCIATES INC /MD/
Low
Report
Form SC 13G/A ARVINAS, INC. Filed by: PRICE T ROWE ASSOCIATES INC /MD/
11/14
07:01 am
arvn
Form SC 13G/A ARVINAS, INC. Filed by: RTW INVESTMENTS, LP
Medium
Report
Form SC 13G/A ARVINAS, INC. Filed by: RTW INVESTMENTS, LP
11/12
05:34 pm
arvn
Form 4 ARVINAS, INC. For: Nov 08 Filed by: Loomis David K
Medium
Report
Form 4 ARVINAS, INC. For: Nov 08 Filed by: Loomis David K
11/12
11:47 am
arvn
Form SC 13G/A ARVINAS, INC. Filed by: BlackRock, Inc.
Low
Report
Form SC 13G/A ARVINAS, INC. Filed by: BlackRock, Inc.
10/30
05:02 pm
arvn
Form 10-Q ARVINAS, INC. For: Sep 30
Medium
Report
Form 10-Q ARVINAS, INC. For: Sep 30
10/30
07:04 am
arvn
Form 8-K ARVINAS, INC. For: Oct 30
Low
Report
Form 8-K ARVINAS, INC. For: Oct 30
10/22
03:23 pm
arvn
Form SC 13G/A ARVINAS, INC. Filed by: BlackRock, Inc.
Low
Report
Form SC 13G/A ARVINAS, INC. Filed by: BlackRock, Inc.
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/16
Form S-8 ARVINAS, INC.
18.8%
11/6 Form 424B5 ARVINAS, INC. 15.1%
6/4 Bayer teams up with biotech firm Arvinas in deal worth up to $750 million [Reuters (UK)] 11.3%
10/23 Arvinas Presents a Platform Update, Including Initial Data from the First Two Clinical Trials of PROTAC® Targeted Protein Degraders 10.5%
11/27 Arvinas to Present at the 31st Annual Piper Jaffray Healthcare Conference 8.8%
3/24 Form 4 ARVINAS, INC. For: Mar 23 Filed by: Houston John G 7.4%
7/25 Arvinas Strengthens Board of Directors with Addition of Leslie Norwalk 7.3%
11/12 Form 8-K ARVINAS, INC. For: Nov 06 6.9%
7/25 Form 8-K ARVINAS, INC. For: Jul 24 5.9%
9/12 Arvinas Inc (NASDAQ: ARVN) is now covered by analysts at BMO Capital Markets. They set an "outperform" rating on the stock. 5.8%
11/6 Form 424B5 ARVINAS, INC. 15.1%
6/4 Bayer teams up with biotech firm Arvinas in deal worth up to $750 million [Reuters (UK)] 11.3%
10/23 Arvinas Presents a Platform Update, Including Initial Data from the First Two Clinical Trials of PROTAC® Targeted Protein Degraders 10.5%
11/27 Arvinas to Present at the 31st Annual Piper Jaffray Healthcare Conference 8.8%
3/24 Form 4 ARVINAS, INC. For: Mar 23 Filed by: Houston John G 7.4%
7/25 Arvinas Strengthens Board of Directors with Addition of Leslie Norwalk 7.3%
11/12 Form 8-K ARVINAS, INC. For: Nov 06 6.9%
7/25 Form 8-K ARVINAS, INC. For: Jul 24 5.9%
9/12 Arvinas Inc (NASDAQ: ARVN) is now covered by analysts at BMO Capital Markets. They set an "outperform" rating on the stock. 5.8%
TOP News Decliners
3/16
Q4/2019 12/31/2019 EPS -0.560 ZacksConsensus N/A ActVsEst N/A - N/A
-18.4%
3/20 Form 4 ARVINAS, INC. For: Mar 18 Filed by: Margus Bradley Albert -11.5%
8/22 Arvinas Inc (NASDAQ: ARVN) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -8.3%
8/5 Q2/2019 6/30/2019 EPS -0.550 ZacksConsensus N/A ActVsEst N/A - N/A -7.9%
10/1 Bayer and Arvinas Unveil Targeted Protein Degradation Joint Venture, Oerth Bio -7.1%
3/10 Arvinas Inc (NASDAQ: ARVN) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $52.00 price target on the stock. -7.1%
2/6 Form 8-K ARVINAS, INC. For: Jan 31 -6.3%
7/31 Form 3 ARVINAS, INC. For: Jul 29 Filed by: Peck Ronald -5.1%
7/16 Form 8-K ARVINAS, INC. For: Jul 15 -4.8%
10/7 Arvinas Inc (NASDAQ: ARVN) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -4.5%
3/20 Form 4 ARVINAS, INC. For: Mar 18 Filed by: Margus Bradley Albert -11.5%
8/22 Arvinas Inc (NASDAQ: ARVN) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -8.3%
8/5 Q2/2019 6/30/2019 EPS -0.550 ZacksConsensus N/A ActVsEst N/A - N/A -7.9%
10/1 Bayer and Arvinas Unveil Targeted Protein Degradation Joint Venture, Oerth Bio -7.1%
3/10 Arvinas Inc (NASDAQ: ARVN) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $52.00 price target on the stock. -7.1%
2/6 Form 8-K ARVINAS, INC. For: Jan 31 -6.3%
7/31 Form 3 ARVINAS, INC. For: Jul 29 Filed by: Peck Ronald -5.1%
7/16 Form 8-K ARVINAS, INC. For: Jul 15 -4.8%
10/7 Arvinas Inc (NASDAQ: ARVN) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -4.5%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: